Search

Your search keyword '"Junttila, Melissa R."' showing total 273 results
Start Over Author "Junttila, Melissa R."
273 results on '"Junttila, Melissa R."'

3. CRAF dimerization with ARAF regulates KRAS-driven tumor growth

Author

Venkatanarayan, Avinashnarayan, Liang, Jason, Yen, Ivana, Shanahan, Frances, Haley, Benjamin, Phu, Lilian, Verschueren, Erik, Hinkle, Trent B., Kan, David, Segal, Ehud, Long, Jason E., Lima, Tony, Liau, Nicholas P.D., Sudhamsu, Jawahar, Li, Jason, Klijn, Christiaan, Piskol, Robert, Junttila, Melissa R., Shaw, Andrey S., Merchant, Mark, Chang, Matthew T., Kirkpatrick, Donald S., and Malek, Shiva

Published
2022
Full Text
View/download PDF

6. Supplementary Figure S1 from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide

Author

Abida, Wassim, primary, Hahn, Andrew W., primary, Shore, Neal, primary, Agarwal, Neeraj, primary, Sieber, Paul, primary, Smith, Matthew R., primary, Dorff, Tanya, primary, Monk, Paul, primary, Rettig, Matthew, primary, Patel, Rupal, primary, Page, Anne, primary, Duff, Maureen, primary, Xu, Rongda, primary, Wang, Jian, primary, Barkund, Shravani, primary, Pankov, Aleksandr, primary, Wang, Amber, primary, Junttila, Melissa R., primary, Multani, Pratik S., primary, Daemen, Anneleen, primary, Chow Maneval, Edna, primary, Logothetis, Christopher J., primary, and Morris, Michael J., primary

Published
2024
Full Text
View/download PDF

7. Data from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide

Author

Abida, Wassim, primary, Hahn, Andrew W., primary, Shore, Neal, primary, Agarwal, Neeraj, primary, Sieber, Paul, primary, Smith, Matthew R., primary, Dorff, Tanya, primary, Monk, Paul, primary, Rettig, Matthew, primary, Patel, Rupal, primary, Page, Anne, primary, Duff, Maureen, primary, Xu, Rongda, primary, Wang, Jian, primary, Barkund, Shravani, primary, Pankov, Aleksandr, primary, Wang, Amber, primary, Junttila, Melissa R., primary, Multani, Pratik S., primary, Daemen, Anneleen, primary, Chow Maneval, Edna, primary, Logothetis, Christopher J., primary, and Morris, Michael J., primary

Published
2024
Full Text
View/download PDF

8. Supplementary Table S1 from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide

Author

Abida, Wassim, primary, Hahn, Andrew W., primary, Shore, Neal, primary, Agarwal, Neeraj, primary, Sieber, Paul, primary, Smith, Matthew R., primary, Dorff, Tanya, primary, Monk, Paul, primary, Rettig, Matthew, primary, Patel, Rupal, primary, Page, Anne, primary, Duff, Maureen, primary, Xu, Rongda, primary, Wang, Jian, primary, Barkund, Shravani, primary, Pankov, Aleksandr, primary, Wang, Amber, primary, Junttila, Melissa R., primary, Multani, Pratik S., primary, Daemen, Anneleen, primary, Chow Maneval, Edna, primary, Logothetis, Christopher J., primary, and Morris, Michael J., primary

Published
2024
Full Text
View/download PDF

9. Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide

Author

Abida, Wassim, primary, Hahn, Andrew W., additional, Shore, Neal, additional, Agarwal, Neeraj, additional, Sieber, Paul, additional, Smith, Matthew R., additional, Dorff, Tanya, additional, Monk, Paul, additional, Rettig, Matthew, additional, Patel, Rupal, additional, Page, Anne, additional, Duff, Maureen, additional, Xu, Rongda, additional, Wang, Jian, additional, Barkund, Shravani, additional, Pankov, Aleksandr, additional, Wang, Amber, additional, Junttila, Melissa R., additional, Multani, Pratik S., additional, Daemen, Anneleen, additional, Chow Maneval, Edna, additional, Logothetis, Christopher J., additional, and Morris, Michael J., additional

Published
2024
Full Text
View/download PDF

10. Compressive stress-mediated p38 activation required for ERα + phenotype in breast cancer

Author

Munne, Pauliina M., Martikainen, Lahja, Räty, Iiris, Bertula, Kia, Nonappa, Ruuska, Janika, Ala-Hongisto, Hanna, Peura, Aino, Hollmann, Babette, Euro, Lilya, Yavuz, Kerim, Patrikainen, Linda, Salmela, Maria, Pokki, Juho, Kivento, Mikko, Väänänen, Juho, Suomi, Tomi, Nevalaita, Liina, Mutka, Minna, Kovanen, Panu, Leidenius, Marjut, Meretoja, Tuomo, Hukkinen, Katja, Monni, Outi, Pouwels, Jeroen, Sahu, Biswajyoti, Mattson, Johanna, Joensuu, Heikki, Heikkilä, Päivi, Elo, Laura L., Metcalfe, Ciara, Junttila, Melissa R., Ikkala, Olli, and Klefström, Juha

Published
2021
Full Text
View/download PDF

11. RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases

Author

Patel, Snahel, Webster, Joshua D., Varfolomeev, Eugene, Kwon, Youngsu C., Cheng, Jason H., Zhang, Juan, Dugger, Debra L., Wickliffe, Kate E., Maltzman, Allie, Sujatha-Bhaskar, Swathi, Bir Kohli, Pawan, Ramaswamy, Sreema, Deshmukh, Gauri, Liederer, Bianca M., Fong, Rina, Hamilton, Greg, Lupardus, Patrick, Caplazi, Patrick, Lee, Wyne P., van Lookeren Campagne, Menno, Johnson, Adam, McKenzie, Brent S., Junttila, Melissa R., Newton, Kim, and Vucic, Domagoj

Published
2020
Full Text
View/download PDF

13. Selective activation of p53-mediated tumour suppression in high-grade tumours

Author

Junttila, Melissa R, Karnezis, Anthony N, Garcia, Daniel, Madriles, Francesc, Kortlever, Roderik M, Rostker, Fanya, Brown Swigart, Lamorna, Pham, David M, Seo, Youngho, Evan, Gerard I, and Martins, Carla P

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Lung, Lung Cancer, Cancer, 2.1 Biological and endogenous factors, Development of treatments and therapeutic interventions, Aetiology, 5.1 Pharmaceuticals, Animals, Carcinoma, Non-Small-Cell Lung, Cell Proliferation, Disease Models, Animal, Gene Expression Regulation, Neoplastic, Lung Neoplasms, Mice, Proto-Oncogene Proteins p21(ras), Tumor Suppressor Protein p53, ras Proteins, General Science & Technology
Abstract

Non-small cell lung carcinoma (NSCLC) is the leading cause of cancer-related death worldwide, with an overall 5-year survival rate of only 10-15%. Deregulation of the Ras pathway is a frequent hallmark of NSCLC, often through mutations that directly activate Kras. p53 is also frequently inactivated in NSCLC and, because oncogenic Ras can be a potent trigger of p53 (ref. 3), it seems likely that oncogenic Ras signalling has a major and persistent role in driving the selection against p53. Hence, pharmacological restoration of p53 is an appealing therapeutic strategy for treating this disease. Here we model the probable therapeutic impact of p53 restoration in a spontaneously evolving mouse model of NSCLC initiated by sporadic oncogenic activation of endogenous Kras. Surprisingly, p53 restoration failed to induce significant regression of established tumours, although it did result in a significant decrease in the relative proportion of high-grade tumours. This is due to selective activation of p53 only in the more aggressive tumour cells within each tumour. Such selective activation of p53 correlates with marked upregulation in Ras signal intensity and induction of the oncogenic signalling sensor p19(ARF)( )(ref. 6). Our data indicate that p53-mediated tumour suppression is triggered only when oncogenic Ras signal flux exceeds a critical threshold. Importantly, the failure of low-level oncogenic Kras to engage p53 reveals inherent limits in the capacity of p53 to restrain early tumour evolution and in the efficacy of therapeutic p53 restoration to eradicate cancers.

Published
2010

15. Supplemental Table 3 from A Druggable FOXA1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung Cancer

Author

Dorso, M., primary, Patel, Payal T., primary, Pankov, Aleksandr, primary, Boyer, Jacob A., primary, Soni, Rajesh K., primary, Del Priore, Isabella S., primary, Hayatt, Omar, primary, Kulick, Amanda, primary, Hagen, Connor J., primary, de Stanchina, Elisa, primary, Junttila, Melissa R., primary, Daemen, Anneleen, primary, Friedman, Lori S., primary, Hendrickson, Ronald C., primary, and Chandarlapaty, Sarat, primary

Published
2023
Full Text
View/download PDF

16. Supplemental Table 2 from A Druggable FOXA1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung Cancer

Author

Dorso, M., primary, Patel, Payal T., primary, Pankov, Aleksandr, primary, Boyer, Jacob A., primary, Soni, Rajesh K., primary, Del Priore, Isabella S., primary, Hayatt, Omar, primary, Kulick, Amanda, primary, Hagen, Connor J., primary, de Stanchina, Elisa, primary, Junttila, Melissa R., primary, Daemen, Anneleen, primary, Friedman, Lori S., primary, Hendrickson, Ronald C., primary, and Chandarlapaty, Sarat, primary

Published
2023
Full Text
View/download PDF

17. Data from A Druggable FOXA1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung Cancer

Author

Dorso, M., primary, Patel, Payal T., primary, Pankov, Aleksandr, primary, Boyer, Jacob A., primary, Soni, Rajesh K., primary, Del Priore, Isabella S., primary, Hayatt, Omar, primary, Kulick, Amanda, primary, Hagen, Connor J., primary, de Stanchina, Elisa, primary, Junttila, Melissa R., primary, Daemen, Anneleen, primary, Friedman, Lori S., primary, Hendrickson, Ronald C., primary, and Chandarlapaty, Sarat, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure S3 from A Druggable FOXA1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung Cancer

Author

Dorso, M., primary, Patel, Payal T., primary, Pankov, Aleksandr, primary, Boyer, Jacob A., primary, Soni, Rajesh K., primary, Del Priore, Isabella S., primary, Hayatt, Omar, primary, Kulick, Amanda, primary, Hagen, Connor J., primary, de Stanchina, Elisa, primary, Junttila, Melissa R., primary, Daemen, Anneleen, primary, Friedman, Lori S., primary, Hendrickson, Ronald C., primary, and Chandarlapaty, Sarat, primary

Published
2023
Full Text
View/download PDF

19. FIGURE 4 from A Druggable FOXA1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung Cancer

Author

Dorso, M., primary, Patel, Payal T., primary, Pankov, Aleksandr, primary, Boyer, Jacob A., primary, Soni, Rajesh K., primary, Del Priore, Isabella S., primary, Hayatt, Omar, primary, Kulick, Amanda, primary, Hagen, Connor J., primary, de Stanchina, Elisa, primary, Junttila, Melissa R., primary, Daemen, Anneleen, primary, Friedman, Lori S., primary, Hendrickson, Ronald C., primary, and Chandarlapaty, Sarat, primary

Published
2023
Full Text
View/download PDF

20. A druggable FOXA1-Glucocorticoid receptor transcriptional axis drives tumor growth in a subset of non-small cell lung cancer

Author

Dorso, Madeline Anne, primary, Patel, Payal T, additional, Pankov, Aleksandr, additional, Boyer, Jacob A, additional, Soni, Rajesh Kumar, additional, Del Priore, Isabella S., additional, Hayatt, Omar, additional, Kulick, Amanda, additional, Hagen, Connor J., additional, de Stanchina, Elisa, additional, Junttila, Melissa R, additional, Daemen, Anneleen, additional, Friedman, Lori S., additional, Hendrickson, Ronald C, additional, and Chandarlapaty, Sarat, additional

Published
2023
Full Text
View/download PDF

21. Abstract 4998: Selective PLK4 inhibition demonstrates synthetic lethality in TRIM37 amplified neuroblastoma and breast cancer models while less selective inhibitors do not

Author

McRee, Siobhan K., primary, Chen, Chelsea, additional, Colas, Christophe, additional, Fang, Wie, additional, Kong, Wayne, additional, Liu, Fang, additional, Long, Jason, additional, Moore, Jared, additional, Pankov, Alex, additional, Shore, Dan, additional, Tan, Joanne, additional, Warne, Robert, additional, Vekariya, Rakesh, additional, Young, Amy, additional, Daemen, Anneleen, additional, Romero, Anthony, additional, Junttila, Melissa R., additional, Friedman, Lori S., additional, and Edgar, Kyle A., additional

Published
2023
Full Text
View/download PDF

22. Abstract 2791: Biomarker strategy for a phase 1 study of ORIC-944, a potent and selective allosteric PRC2 inhibitor, in patients with metastatic prostate cancer

Author

Daemen, Anneleen, primary, Yuen, Natalie, additional, Pankov, Aleksandr, additional, Ariazi, Eric A., additional, Katewa, Subhash D., additional, Duong, Frank L., additional, Wang, Amber, additional, Barkund, Shravani, additional, Kaushik, Shelly, additional, Sun, Jessica D., additional, Friedman, Lori S., additional, and Junttila, Melissa R., additional

Published
2023
Full Text
View/download PDF

23. Supplementary Table S1 from Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1

Author

Laine, Anni, primary, Sihto, Harri, primary, Come, Christophe, primary, Rosenfeldt, Mathias T., primary, Zwolinska, Aleksandra, primary, Niemelä, Minna, primary, Khanna, Anchit, primary, Chan, Edward K., primary, Kähäri, Veli-Matti, primary, Kellokumpu-Lehtinen, Pirkko-Liisa, primary, Sansom, Owen J., primary, Evan, Gerard I., primary, Junttila, Melissa R., primary, Ryan, Kevin M., primary, Marine, Jean-Christophe, primary, Joensuu, Heikki, primary, and Westermarck, Jukka, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Methods from Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1

Author

Laine, Anni, primary, Sihto, Harri, primary, Come, Christophe, primary, Rosenfeldt, Mathias T., primary, Zwolinska, Aleksandra, primary, Niemelä, Minna, primary, Khanna, Anchit, primary, Chan, Edward K., primary, Kähäri, Veli-Matti, primary, Kellokumpu-Lehtinen, Pirkko-Liisa, primary, Sansom, Owen J., primary, Evan, Gerard I., primary, Junttila, Melissa R., primary, Ryan, Kevin M., primary, Marine, Jean-Christophe, primary, Joensuu, Heikki, primary, and Westermarck, Jukka, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Data from Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy

Author

Dominguez, Claudia X., primary, Müller, Sören, primary, Keerthivasan, Shilpa, primary, Koeppen, Hartmut, primary, Hung, Jeffrey, primary, Gierke, Sarah, primary, Breart, Beatrice, primary, Foreman, Oded, primary, Bainbridge, Travis W., primary, Castiglioni, Alessandra, primary, Senbabaoglu, Yasin, primary, Modrusan, Zora, primary, Liang, Yuxin, primary, Junttila, Melissa R., primary, Klijn, Christiaan, primary, Bourgon, Richard, primary, and Turley, Shannon J., primary

Published
2023
Full Text
View/download PDF

26. Data from Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1

Author

Laine, Anni, primary, Sihto, Harri, primary, Come, Christophe, primary, Rosenfeldt, Mathias T., primary, Zwolinska, Aleksandra, primary, Niemelä, Minna, primary, Khanna, Anchit, primary, Chan, Edward K., primary, Kähäri, Veli-Matti, primary, Kellokumpu-Lehtinen, Pirkko-Liisa, primary, Sansom, Owen J., primary, Evan, Gerard I., primary, Junttila, Melissa R., primary, Ryan, Kevin M., primary, Marine, Jean-Christophe, primary, Joensuu, Heikki, primary, and Westermarck, Jukka, primary

Published
2023
Full Text
View/download PDF

27. Data from Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy

Author

Dominguez, Claudia X., primary, Müller, Sören, primary, Keerthivasan, Shilpa, primary, Koeppen, Hartmut, primary, Hung, Jeffrey, primary, Gierke, Sarah, primary, Breart, Beatrice, primary, Foreman, Oded, primary, Bainbridge, Travis W., primary, Castiglioni, Alessandra, primary, Senbabaoglu, Yasin, primary, Modrusan, Zora, primary, Liang, Yuxin, primary, Junttila, Melissa R., primary, Klijn, Christiaan, primary, Bourgon, Richard, primary, and Turley, Shannon J., primary

Published
2023
Full Text
View/download PDF

28. Supplemental Fig 1,2,3 from Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer

Author

Junttila, Melissa R., primary, Devasthali, Vidusha, primary, Cheng, Jason H., primary, Castillo, Joseph, primary, Metcalfe, Ciara, primary, Clermont, Anne C., primary, Otter, Douglas Den, primary, Chan, Emily, primary, Bou-Reslan, Hani, primary, Cao, Tim, primary, Forrest, William, primary, Nannini, Michelle A., primary, French, Dorothy, primary, Carano, Richard, primary, Merchant, Mark, primary, Hoeflich, Klaus P., primary, and Singh, Mallika, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure 3 from Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1

Author

Laine, Anni, primary, Sihto, Harri, primary, Come, Christophe, primary, Rosenfeldt, Mathias T., primary, Zwolinska, Aleksandra, primary, Niemelä, Minna, primary, Khanna, Anchit, primary, Chan, Edward K., primary, Kähäri, Veli-Matti, primary, Kellokumpu-Lehtinen, Pirkko-Liisa, primary, Sansom, Owen J., primary, Evan, Gerard I., primary, Junttila, Melissa R., primary, Ryan, Kevin M., primary, Marine, Jean-Christophe, primary, Joensuu, Heikki, primary, and Westermarck, Jukka, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 4 from Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1

Author

Laine, Anni, primary, Sihto, Harri, primary, Come, Christophe, primary, Rosenfeldt, Mathias T., primary, Zwolinska, Aleksandra, primary, Niemelä, Minna, primary, Khanna, Anchit, primary, Chan, Edward K., primary, Kähäri, Veli-Matti, primary, Kellokumpu-Lehtinen, Pirkko-Liisa, primary, Sansom, Owen J., primary, Evan, Gerard I., primary, Junttila, Melissa R., primary, Ryan, Kevin M., primary, Marine, Jean-Christophe, primary, Joensuu, Heikki, primary, and Westermarck, Jukka, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure 2 from Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1

Author

Laine, Anni, primary, Sihto, Harri, primary, Come, Christophe, primary, Rosenfeldt, Mathias T., primary, Zwolinska, Aleksandra, primary, Niemelä, Minna, primary, Khanna, Anchit, primary, Chan, Edward K., primary, Kähäri, Veli-Matti, primary, Kellokumpu-Lehtinen, Pirkko-Liisa, primary, Sansom, Owen J., primary, Evan, Gerard I., primary, Junttila, Melissa R., primary, Ryan, Kevin M., primary, Marine, Jean-Christophe, primary, Joensuu, Heikki, primary, and Westermarck, Jukka, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 1 from Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1

Author

Laine, Anni, primary, Sihto, Harri, primary, Come, Christophe, primary, Rosenfeldt, Mathias T., primary, Zwolinska, Aleksandra, primary, Niemelä, Minna, primary, Khanna, Anchit, primary, Chan, Edward K., primary, Kähäri, Veli-Matti, primary, Kellokumpu-Lehtinen, Pirkko-Liisa, primary, Sansom, Owen J., primary, Evan, Gerard I., primary, Junttila, Melissa R., primary, Ryan, Kevin M., primary, Marine, Jean-Christophe, primary, Joensuu, Heikki, primary, and Westermarck, Jukka, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 5 from Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1

Author

Laine, Anni, primary, Sihto, Harri, primary, Come, Christophe, primary, Rosenfeldt, Mathias T., primary, Zwolinska, Aleksandra, primary, Niemelä, Minna, primary, Khanna, Anchit, primary, Chan, Edward K., primary, Kähäri, Veli-Matti, primary, Kellokumpu-Lehtinen, Pirkko-Liisa, primary, Sansom, Owen J., primary, Evan, Gerard I., primary, Junttila, Melissa R., primary, Ryan, Kevin M., primary, Marine, Jean-Christophe, primary, Joensuu, Heikki, primary, and Westermarck, Jukka, primary

Published
2023
Full Text
View/download PDF

36. Figures S1-S14, Tables S1-S2 from Tumor Elastography and Its Association with Collagen and the Tumor Microenvironment

Author

Riegler, Johannes, primary, Labyed, Yassin, primary, Rosenzweig, Stephen, primary, Javinal, Vincent, primary, Castiglioni, Alessandra, primary, Dominguez, Claudia X., primary, Long, Jason E., primary, Li, Qingling, primary, Sandoval, Wendy, primary, Junttila, Melissa R., primary, Turley, Shannon J., primary, Schartner, Jill, primary, and Carano, Richard A.D., primary

Published
2023
Full Text
View/download PDF

37. Supplementary File from Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma

Author

Daemen, Anneleen, primary, Cooper, Jonathan E., primary, Myrta, Szymon, primary, Wongchenko, Matthew J., primary, Lin, Eva, primary, Long, Jason E., primary, Foreman, Oded, primary, Modrusan, Zora, primary, Tremayne, Jarrod R., primary, de la Cruz, Cecile C., primary, Merchant, Mark, primary, Martin, Scott E., primary, Yan, Yibing, primary, and Junttila, Melissa R., primary

Published
2023
Full Text
View/download PDF

38. Figure S1 from Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma

Author

Daemen, Anneleen, primary, Cooper, Jonathan E., primary, Myrta, Szymon, primary, Wongchenko, Matthew J., primary, Lin, Eva, primary, Long, Jason E., primary, Foreman, Oded, primary, Modrusan, Zora, primary, Tremayne, Jarrod R., primary, de la Cruz, Cecile C., primary, Merchant, Mark, primary, Martin, Scott E., primary, Yan, Yibing, primary, and Junttila, Melissa R., primary

Published
2023
Full Text
View/download PDF

40. Supplemental Figure 1-5 from IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody

Author

Li, Ji, primary, Ybarra, Ryan, primary, Mak, Judy, primary, Herault, Aurelie, primary, De Almeida, Patricia, primary, Arrazate, Alfonso, primary, Ziai, James, primary, Totpal, Klara, primary, Junttila, Melissa R., primary, Walsh, Kevin B., primary, and Junttila, Teemu T., primary

Published
2023
Full Text
View/download PDF

41. Data from PME-1 Protects Extracellular Signal-Regulated Kinase Pathway Activity from Protein Phosphatase 2A–Mediated Inactivation in Human Malignant Glioma

Author

Puustinen, Pietri, primary, Junttila, Melissa R., primary, Vanhatupa, Sari, primary, Sablina, Anna A., primary, Hector, Melissa E., primary, Teittinen, Kaisa, primary, Raheem, Olayinka, primary, Ketola, Kirsi, primary, Lin, Shujun, primary, Kast, Juergen, primary, Haapasalo, Hannu, primary, Hahn, William C., primary, and Westermarck, Jukka, primary

Published
2023
Full Text
View/download PDF

42. Data from Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells

Author

Junttila, Teemu T., primary, Li, Ji, primary, Johnston, Jennifer, primary, Hristopoulos, Maria, primary, Clark, Robyn, primary, Ellerman, Diego, primary, Wang, Bu-Er, primary, Li, Yijin, primary, Mathieu, Mary, primary, Li, Guangmin, primary, Young, Judy, primary, Luis, Elizabeth, primary, Lewis Phillips, Gail, primary, Stefanich, Eric, primary, Spiess, Christoph, primary, Polson, Andrew, primary, Irving, Bryan, primary, Scheer, Justin M., primary, Junttila, Melissa R., primary, Dennis, Mark S., primary, Kelley, Robert, primary, Totpal, Klara, primary, and Ebens, Allen, primary

Published
2023
Full Text
View/download PDF

43. Supplemental Figures 1 - 8 from Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells

Author

Junttila, Teemu T., primary, Li, Ji, primary, Johnston, Jennifer, primary, Hristopoulos, Maria, primary, Clark, Robyn, primary, Ellerman, Diego, primary, Wang, Bu-Er, primary, Li, Yijin, primary, Mathieu, Mary, primary, Li, Guangmin, primary, Young, Judy, primary, Luis, Elizabeth, primary, Lewis Phillips, Gail, primary, Stefanich, Eric, primary, Spiess, Christoph, primary, Polson, Andrew, primary, Irving, Bryan, primary, Scheer, Justin M., primary, Junttila, Melissa R., primary, Dennis, Mark S., primary, Kelley, Robert, primary, Totpal, Klara, primary, and Ebens, Allen, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Tables 1-3, Figures 1-6 from PME-1 Protects Extracellular Signal-Regulated Kinase Pathway Activity from Protein Phosphatase 2A–Mediated Inactivation in Human Malignant Glioma

Author

Puustinen, Pietri, primary, Junttila, Melissa R., primary, Vanhatupa, Sari, primary, Sablina, Anna A., primary, Hector, Melissa E., primary, Teittinen, Kaisa, primary, Raheem, Olayinka, primary, Ketola, Kirsi, primary, Lin, Shujun, primary, Kast, Juergen, primary, Haapasalo, Hannu, primary, Hahn, William C., primary, and Westermarck, Jukka, primary

Published
2023
Full Text
View/download PDF

46. CD73 Inhibition Reverses Immunosuppression and Has Potential As an Immunomodulatory Therapy in Patients with Multiple Myeloma

Author

Junttila, Melissa R, primary, Ray, Arghya, additional, Warne, Robert, additional, Chen, Xi R, additional, Du, Ting, additional, Lui, Fang, additional, Katewa, Subhash, additional, Blank, Brian, additional, Moore, Jared, additional, Ndubaku, Chudi, additional, Colas, Christophe, additional, Multani, Pratik S, additional, Nadeem, Omar, additional, Chauhan, Dharminder, additional, Anderson, Kenneth C., additional, and Friedman, Lori, additional

Published
2022
Full Text
View/download PDF

48. Translational value of mouse models in oncology drug development

Author

Gould, Stephen E., Junttila, Melissa R., and de Sauvage, Frederic J.

Subjects
Models, Innovations, Cancer treatment -- Innovations, Animal experimentation -- Models, Cancer -- Care and treatment
Abstract

Over the past half century, oncology drug development has shifted from an empirical approach of broadly reducing cell proliferation or increasing cell death to a target-based approach aimed at well-defined [...], Much has been written about the advantages and disadvantages of various oncology model systems, with the overall finding that these models lack the predictive power required to translate preclinical efficacy into clinical activity. Despite assertions that some preclinical model systems are superior to others, no single model can suffice to inform preclinical target validation and molecule selection. This perspective provides a balanced albeit critical view of these claims of superiority and outlines a framework for the proper use of existing preclinical models for drug testing and discovery. We also highlight gaps in oncology mouse models and discuss general and pervasive model-independent shortcomings in preclinical oncology work, and we propose ways to address these issues.

Published
2015
Full Text
View/download PDF

49. EHMT2 methyltransferase governs cell identity in the lung and is required for KRAS G12D tumor development and propagation

Author

Pribluda, Ariel, primary, Daemen, Anneleen, additional, Lima, Anthony Nelson, additional, Wang, Xi, additional, Hafner, Marc, additional, Poon, Chungkee, additional, Modrusan, Zora, additional, Katakam, Anand Kumar, additional, Foreman, Oded, additional, Eastham, Jefferey, additional, Hung, Jefferey, additional, Haley, Benjamin, additional, Garcia, Julia T, additional, Jackson, Erica L, additional, and Junttila, Melissa R, additional

Published
2022
Full Text
View/download PDF

50. Abstract 2633: Discovery of novel, highly selective inhibitors of PLK4 that demonstrate in vivo regressions in TRIM37 high xenografts

Author

Edgar, Kyle A., primary, Young, Amy, additional, Moore, Jared, additional, Chen, Xi, additional, Fang, Wei, additional, Chang, Jae H., additional, Kong, Wayne, additional, Long, Jason E., additional, Pankov, Aleksandr, additional, Daemen, Anneleen, additional, Shore, Daniel G., additional, Warne, Robert, additional, Gibbons, Paul, additional, Ndubaku, Chudi O., additional, Junttila, Melissa R., additional, and Friedman, Lori S., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results